|
 |
 |
|
Agennix
Agennix, a privately held biopharmaceutical company, is the world leader in the development of Talactoferrin Alfa, an immuno-stimulatory protein for pharmaceutical use. Talactoferrin has demonstrated efficacy in Phase 2 placebo-controlled trials in non-small cell lung cancer and diabetic foot ulcers. The company is preparing to initiate Phase 3 clinical trials in these indications.
|
|
|
 |
|
Fairway Medical Technologies
Fairway Medical Technologies is an integrated medical device company with broad experience and expertise in the commercialization of innovative technologies as well as contract design and manufacturing services for the life science industry.
|
|
|
 |
|
Kardia Therapeutics, Inc.
Kardia Therapeutics, Inc. is a research-stage biotechnology company focused on the development of cardiac regenerative therapies in the areas myocardial infarction and heart failure. Kardia Therapeutics’ portfolio of technologies utilizes three related approaches: 1) Adult Cardiac Progenitor Cells, 2) Stem Cell Optimization Technologies, and 3) Homing/Growth Factor Therapies. Because the heart has a limited capacity for self-regeneration, Kardia’s technologies have the potential to offer significantly improved patient outcomes compared to existing treatments. For Additional Information Contact: Dr. Rick Schwarz
|
|
|
|
 |
|
Kryptiq Corporation
Kryptiq is the leading provider of workflow connectivity solutions for healthcare. Kryptiq streamlines healthcare communications among patients, providers, pharmacies and healthplans with secure messaging, electronic prescribing, disease management, and contract management technologies. By integrating these solutions with existing systems and applications, Kryptiq enables the trusted transport of health information where and when it is needed.
|
|
|
 |
|
Molecular Logix, Inc.
MLX is a drug discovery company located in The Woodlands, Texas, that seeks to discover novel therapeutics through the application of rationale protein engineering technologies. The company is currently developing protein-based drugs to treat cancer by interfering with established tumor growth factor pathways.
|
|
|
 |
|
Opexa Therapeutics (NASDAQ: OPXA)
Opexa Therapeutics is a publicly-traded cellular therapy company located in the Woodlands, TX (outside of Houston) with two proprietary, broad technical therapeutic platforms: T-cell vaccination and autologous stem cell therapy. Opexa Therapeutics is developing autologous cellular therapies to treat several major illnesses, including multiple sclerosis, cardiovascular disease, and diabetes.
|
|
|
 |
|
Progression Therapeutics
Progression Therapeutics is a biotechnology company focused on the treatment of primary and metastatic cancer. The Company currently has multiple products in various stages of evaluation, including a novel tumor suppressor gene product that has demonstrated potent anti-tumor activity both in vitro and in vivo. For Additional Information Contact: Dr. Caroline Popper
|
|
|
 |
|
Prokaryon Technologies, Inc.
Prokaryon Technologies, Inc., is a animal health company that develops solutions for the prevention and control of economically devastating diseases in food animals. The focus of the company is the discovery, development, and commercialization of innovative veterinary products. Prokaryon's lead product is a genomics-derived vaccine to prevent shipping fever in cattle. For Additional Information Contact: Dr. Caroline Popper
|
|
|
 |
|
Relievant MedSystems
Relievant MedSystems is a medical device company developing novel products to treat lower back pain using a minimally invasive therapeutic approach. The company was founded in 2004 and is headquartered in San Francisco, California.
|
|
|
 |
|
Sapphire Therapeutics
Sapphire is a biopharmaceutical company committed to developing and commercializing promising compounds that are ready for clinical or pre-clinical testing in oncologic and metabolic disease. The most advanced drug candidate in Sapphire's pipeline is a small molecule ghrelin agonist that is currently in Phase II human clinical trials for cancer cachexia.
|
|
|
